廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    13.04
    +0.26 (+2.03%)
     
  • 富時100

    7,952.37
    +20.39 (+0.26%)
     
  • 紐約期油

    82.42
    +1.07 (+1.32%)
     
  • 金價

    2,229.40
    +16.70 (+0.75%)
     
  • 美元

    7.8248
    +0.0018 (+0.02%)
     
  • 人民幣

    0.9233
    +0.0001 (+0.01%)
     
  • 日圓

    0.0514
    -0.0000 (-0.04%)
     
  • 歐元

    8.4378
    -0.0314 (-0.37%)
     
  • Bitcoin

    70,601.41
    +412.87 (+0.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo

  • Exelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS).

  • CONTACT-03 is sponsored by Roche Holdings AG (OTC: RHHBY) and co-funded by Exelixis.

  • The study evaluated Cabometyx (cabozantinib) combined with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear or non-clear renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy.

  • Three months ago, the companies disclosed a similarly disappointing outcome for the CONTACT-01 study.

  • Tecentriq plus Cabometyx failed to meet its primary endpoint of overall survival at the final analysis compared to chemotherapy.

  • CONTACT-02, focused on metastatic castration-resistant prostate cancer, is slated to read out later this year.

  • The CONTACT-03 trial enrolled 522 patients with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy, either as part of a combination or as a monotherapy.

  • More data will be presented at a medical meeting, Exelixis said.

  • Price Action: EXEL shares are down 1.89% at $16.86 on the last check Friday.

  • Photo Via Company

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.